Introduction: Adult-onset Still's disease (AOSD) is a rare multisystem autoinflammatory disorder of unknown etiology, with clinical and biological similarities with the juvenile form (sJIA).The pivotal role of interleukin (IL)-1 gives rise to the use of IL-1 inhibitors in treating resistant cases.Areas covered: This review focuses on canakinumab, a fully human anti-IL-1β antibody, as treatment for AOSD. The data obtained from case reports and case series on AOSD and two double-blind, randomized, placebo-controlled Phase III trial on sJIA are analyzed. Efficacy and safety profiles of canakinumab are discussed.Expert opinion: There is no unanimous consensus on how to treat with IL-1 inhibitors. Many reviews have focused primarily on anakinra, but the accumulating data for canakinumab have emerged. The choice of treatment is a relevant issue for patients and the national health services. The available data for canakinumab indicate that this drug in AOSD patients is effective and well tolerated.

中文翻译：

---

Canakinumab用于治疗成人发作的Still病。

简介：成年性斯蒂尔病（AOSD）是一种罕见的病因不明的多系统自身炎症性疾病，与少年型（sJIA）的临床和生物学相似性。白介素（IL）-1的关键作用促使人们使用IL。 -1抑制剂在治疗耐药病例中的研究范围：本综述重点关注完全人抗IL-1β抗体canakinumab作为AOSD的治疗方法。分析了从AOSD的病例报告和病例系列以及sJIA的两项双盲，随机，安慰剂对照的III期临床试验中获得的数据。讨论了canakinumab的疗效和安全性概况。专家意见：关于如何使用IL-1抑制剂进行治疗尚无共识。许多评论主要集中在anakinra上，但是canakinumab的累积数据已经出现。治疗的选择是患者和国家卫生服务的相关问题。canakinumab的可用数据表明，该药物在AOSD患者中有效且耐受性良好。